The potential of FDG-PET and MRI in monitoring response to treatment in lymphoma is reviewed. Both FDG-PET and MRI can provide whole body imaging. Both also share the advantage of combining functional and anatomical information. At present, hybrid FDG-PET and MDCT is the best technique for monitoring response to treatment, especially early response to treatment. Early assessment of response to treatment has the potential to tailor therapy. MR imaging is useful especially in assessing bone marrow and central nervous system involvement.

Author

Alain Rahmouni, Alain Luciani and Emmanuel Itti

Contact Details

Corresponding address:
Alain Rahmouni, MD,
Imagerie Medicale, CHU Henri Mondor,
51, avenue du Marechal de Lattre de Tassigny,
94010 Creteil cedex, France.

Reference

ICIS Cancer Imaging Volume 5 Special Issue A
DOI: 10.1102/1470-7330.2005.0038

Date Posted

24 November 2005

Screen PDF

Size

381.64 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	5 seconds
64 Kb/s (ISDN):	47 seconds
33.3 Kb/s (Typical Modem):	1 minute 31 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.